GT Biopharma prices USD 7.75 million private placement of Series M preferred, warrants
Bitget2026/09/21 20:11- GT Biopharma expanded a private placement to raise USD 7.75 million through Series M 10% convertible preferred stock and accompanying warrants.
- Amendment increased issuance to 8,611 shares of preferred stock, up from 8,278, with warrants sized to the conversion shares.
- Purchasers received greenshoe rights for up to USD 31.21 million of additional preferred stock purchases, subject to adjustments.
- Transaction structured as an unregistered offering under Rule 506(b) of Regulation D.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitmine Buys 9,587 ETH as Holdings Near 5% of Ethereum Supply
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
Crypto prices
More
